Journal Information
Vol. 44. Issue. 1.January - February 2024
Pages 1-118
Share
Share
Download PDF
More article options
Vol. 44. Issue. 1.January - February 2024
Pages 1-118
Letter to the Editor
Full text access
I’m a Nephrologist and I give urea to my patients. SIAD in oncological patients
Soy nefrólogo y trato a mis pacientes con urea. SIAD en pacientes oncológicos
Visits
1824
Círia Sousaa, Inês Coelhob, Hugo Ferreirab, Teresa Chuvab, Ana Paivab, José Maximino Costab,
Corresponding author
a Division of Nephrology, Department of Medicine, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal
b Division of Nephrology, Department of Medicine, Instituto Português de Oncologia do Porto, Porto, Portugal
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Tables (2)
Table 1. Clinical and laboratory characteristics of patients with the Syndrome of inappropriate antidiuresis.
Table 2. Treatment parameters and outcomes.
Show moreShow less
Full Text
Dear Editor:

Syndrome of inappropriate antidiuresis (SIAD) is an emerging problem in cancer patients and is responsible for one-third of cancer-related hyponatremia. SIAD can cause reduced quality of life, longer hospital admissions, and increased costs.1

Fluid restriction (FR) and increasing renal free water excretion are the basis of chronic cancer-related hyponatremia treatment. International guidelines put loop diuretics, urea, vaptans, or demeclocycline after FR, as first-line treatments.2,3

Urea had increased interest in the last years due to its effectiveness, and good safety profile.4 We hypothesized that urea is a good option in the treatment of SIAD in cancer patients.

We enrolled 11 cancer patients who were diagnosed with SIAD, from August 2021 until March 2022, that were treated with oral urea. We collected serum sodium (sNa) at baseline, 24h after starting treatment, and after that on basis of natremia evolution. We also record the time to reach sNa above 130mEq/L and 135mEq/L, the dose and duration of treatment and reported side effects.

We observed that severe and chronic hyponatremia was present at admission in 82% of patients. Mean sNa was 121[±3]mEq/L and all have normal kidney function (Table 1). After 24h of treatment a mean increase of 3[±1]mEq/L occurred. The median time to reach sNa levels ≥130mEq/L and ≥135mEq/L were 5 (IQR 3–15, range 2–110) and 9 (IQR 4–20, range 2–60) days, respectively. Patients were treated with urea for a median of 25 days (IQR 10–178, range 3–224) (Table 2). In 4 patients we have records of urea distaste but not motivated discontinuation of treatment. Neither renal impairment, nor significant alterations of other electrolytes were detected. Mortality at end of study was 18% and no link to hyponatremia was identified.

Table 1.

Clinical and laboratory characteristics of patients with the Syndrome of inappropriate antidiuresis.

Patient no.  Sex  Age (yr)  Presumed cause of SIAD  Cancer  Metastatic disease  sNa (mEq/L)  UOsm (mOsm/kg)  UNa (mEq/L)  sCr (mg/dL)  sUrea (mg/dL)  Uric acid (mg/dL) 
62  Paraneoplastic  Lung squamous cell carcinoma  No  118  577  97  0.78  12.60  10.80 
74  Paraneoplastic  Lung adenocarcinoma  Yes  120  631  79  0.60  24.60  2.00 
74  Paraneoplastic  Hypopharyngeal squamous cell carcinoma  No  123  386  41  0.54  25.00  5.20 
55  Multifactorial  Small cell lung cancer  Yes  125  719  167  0.42  20.40  2.00 
52  Paraneoplastic  Small cell lung cancer  No  124  230  76  0.49  36.60  2.80 
60  Paraneoplastic  Small cell lung cancer  Yes  121  626  162  0.50  36.00  1.80 
72  Paraneoplastic  Small cell lung cancer  No  118  304  111  0.36  16.20  1.60 
54  Paraneoplastic  Small cell lung cancer  Yes  122  558  168  0.43  16.80  4.40 
60  Paraneoplastic  Small cell lung cancer  Yes  126  674  49  0.70  30.00  1.70 
10  46  Paraneoplastic  Breast carcinoma  Yes  124  172  30  0.86  44.40  4.80 
11  47  Chemotherapy related  Non-Hodgkin's Lymphoma  No  119  574  180  0.26  26.40  3.20 

F, female; M, male; NA, not applicable; sCr, serum creatine, sNa, serum sodium, UNa, urine sodium; UOsm, urine osmolality; sUrea, serum urea, yr, years.

Table 2.

Treatment parameters and outcomes.

Patient no.  Treatment of hyponatremiaOutcomes
  Previous treatment to Urea  Urea dose (g/day)  Urea treatment (days)  24h sNa (mEq/L)  Days until sNa130mEq/L  Days until sNa135mEq/L  Patients on treatment  Mortality 
Fluid restriction  20  195  NA  Yes  No 
Hypertonic saline plus fluid restriction  20  25  124  22  No  Yes 
Fluid restriction  20  173  NA  110  NA  Yes  No 
Hypertonic saline 3%  20  224  129  Yes  No 
Hypertonic saline 3%  20  129  No  Yes 
Hypertonic saline 3%  30  26  124  11  No  No 
Normal saline 0.9%  30  102  119  19  19  Yes  No 
Fluid restriction plus normal saline 0.9% plus Loop diuretics  20  125  14  Yes  No 
Normal saline 0.9%  20  12  130  Yes  No 
10  Fluid restriction after Normal saline 0.9%  20  11  127  15  NA  Yes  No 
11  Hypertonic saline 3%  20  10  123  Yes  No 

sNa=plasma sodium; sNa24=serum sodium at 24h of treatment; NA=not available.

We endorse that in SIAD patients is particularly relevant to understand the whole-body volume regulation. In early SIAD stages, water retention is induced by antidiuretic stimulus, but with its continuity, natriuresis occurs to regulate de volume distribution between extracellular and intracellular space.5

The imbalance between water and sodium makes urea an interesting treatment option, because its effects not only involve osmotic diuresis but also the urinary sodium excretion.5

Urea is stored in inner medulla and is responsible for 50% of solutes in this segment. The urea transporters (UT), who are distributed in thin limb of loop of the Henle (UT-A2) and in inner medullary collecting duct (UT-A1/3), are responsible for this urea stored and recycling process.5,6

Urea is secreted in the initial portion of thick ascending limb of Henle, promoting an increase in intratubular urea concentration by to 110% of initial filtered load. Next segments are relatively impermeable to urea until the outer medullary collecting duct. At terminal inner medullary collecting duct (IMCD) permeability will increase and only 50% of urea remain in the lumen. In the presence of ADH, 20% is absorbed through the UT-A1 transporters in apical membrane in IMCD cells and exits this cell via UT-A3 in basolateral membranes, which leads to a total excreted load of 30%.6

Previous studies suggested that UT-A1/A3 are saturable transporters.7 This may explain why an amount of urea reaching this region is not transported to the medullary region, remaining in the tubular lumen, thus increasing osmotic diuresis.

Recent study working groups have include urea as second-line treatment strategy for managing SIAD.2,3 In cancer patients removing the primary cause sometimes is not possible and additional treatment are needed. These patients have a higher risk of hypovolemic status and FR institution is difficult in needs of chemotherapeutic infusions.8

In a cohort of cancer patients with SIAD treated with urea, 40% of the patients reached sodium above 130mEq/L during the first 24h of treatment and 86.1% reached eunatremia during the first month.9 In our study the time required to attain sodium above 130mEq/L varied–median of 5 (IQR 3–15, range 2–110) days, but was achieved in all patients. The eunatremia was reached in 64% (n=7) patients.

Urea was generally well tolerated, despite 50% of patients refers unpleasant taste it was not enough to interrupt the treatment.2,3 Demyelination syndrome has not been described in patients treated with urea, moreover it can even have a cerebral protective effect when overcorrection occurs.10

Other SIAD treatment option includes vaptans. The first study that compared vaptans to urea concluded that these patients could be treated with the same safety, efficacy and tolerance with either drugs.4 However, European guidelines do not encourage the use of vaptans in SIAD.2

Our study reinforces that oral urea in chronic hyponatremia cancer patients appears to be effective, safe, and well tolerated, with no serious adverse events reported. Urea can be used for a long period of time in ambulatory patients, becoming a therapeutic approach in cancer patients, which can possibly reduce hospitalizations, improve quality of life and survival with a good cost-effectiveness profile.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest

None declared.

References
[1]
B. Winzeler, et al.
Long-term outcome of profound hyponatremia: a prospective 12 months followup study.
Eur J Endocrinol, 175 (2016), pp. 499-507
[2]
G. Spasovski, et al.
Hyponatraemia Guideline Development Group: clinical practice guideline on diagnosis and treatment of hyponatraemia.
Eur J Endocrinol, 170 (2014), pp. G1-G47
[3]
J.G. Verbalis, G.A. Goldsmith, et al.
Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations.
Am J Med, 126 (2013), pp. S1-S42
[4]
A. Soupart, M. Coffernils, B. Couturier, F. Gankam-Kengne, G. Decaux, et al.
Efficacy and tolerance of urea compared with vaptans for longterm treatment of patients with SIADH.
Clin J Am Soc Nephrol, 7 (2012), pp. 742-747
[5]
J. Verbalis.
Whole-body volume regulation and escape from antidiuresis.
Am J Med, 119 (2006), pp. S21-S29
[6]
R. Burton, P. Theodore.
Clinical physiology of acid-base and electrolyte disorders (clinical physiology of acid base & electrolyte disorders).
5th ed., McGraw-Hill Professional Publishing, (2000),
[7]
C.L. Chou, M.A. Knepper.
Inhibition of urea transport in inner medullary collecting duct by phloretin and urea analogues.
Am J Physiol, 257 (1989), pp. F359-F365
[8]
J.J. Castillo, M. Vincent, E. Justice.
Diagnosis and management of hyponatremia in cancer patients.
Oncologist, 17 (2012), pp. 756-765
[9]
A. Nervo, et al.
Urea in cancer patients with chronic SIAD-induced hyponatremia: old drug, new evidence.
Clin Endocrinol, 90 (2019), pp. 842-848
[10]
A. Soupart, B. Schroeder, G. Decaux.
Treatment of hyponatraemia by urea decreases risks of brain complications in rats Brain osmolyte contents analysis 2007.
Nephrol Dial Transplan, 7 (2007), pp. 1856-1863
Copyright © 2022. Sociedad Española de Nefrología
Idiomas
Nefrología (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?